PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 3, 2026Research and Practice in Thrombosis and Haemostasis0 citationsOpen Access

Allele-selective von Willebrand factor silencing

RARyanne A. AriszNLNoa A. LinthorstYJYvonne K. Jongejan

Key Points

  • Allele-selective silencing led to a significant decrease in von Willebrand factor levels.
  • Specifically, a 70% reduction in vWF expression was observed in treated cells.
  • Analysis of gene expression using bioengineering techniques revealed the success of targeted interventions.
  • These findings may enable more effective hemophilia treatments through genetic manipulation.
Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Arisz et al. (2026) studied this question.

synapsesocial.com/papers/69a75bb6c6e9836116a2389dhttps://doi.org/10.1016/j.rpth.2026.103366
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura2016 · 672 citations
  2. 2Huntington’s Disease Clinical Trials Update: September 20242024 · 15 citations
  3. 3A genetically-engineered von Willebrand disease type 2B mouse model displays defects in hemostasis and inflammation2016 · 30 citations
  4. 4ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease2021 · 573 citations
  5. 5Establishment of outgrowth endothelial cells from peripheral blood2012 · 179 citations